Why Is Coinbase Stock Going Down?
Every way you look at it, Coinbase has had a…
Sell
42
NARI Quote, Financials, Valuation and Earnings
Last price:
$52.95
Seasonality move
:
-4.43%
Day range:
$52.42 - $53.95
52-week range:
$36.73 - $66.61
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.35x
P/B ratio:
7.13x
Volume:
510.2K
Avg. volume:
956.2K
1-year change:
-19.5%
Market cap:
$3.1B
Revenue:
$493.6M
EPS (TTM):
-$1.35
Analysts' Opinion
-
Consensus RatingInari Medical has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $66.59, Inari Medical has an estimated upside of 25.71% from its current price of $52.97.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $50.00 representing 5.61% downside risk from its current price of $52.97.
Fair Value
-
According to the consensus of 14 analysts, Inari Medical has 25.71% upside to fair value with a price target of $66.59 per share.
NARI vs. S&P 500
-
Over the past 5 trading days, Inari Medical has underperformed the S&P 500 by -3.3% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Inari Medical does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Inari Medical has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Inari Medical reported revenues of $153.4M.
Earnings Growth
-
Inari Medical earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Inari Medical reported earnings per share of -$0.31.
Enterprise value:
3B
EV / Invested capital:
6.88x
Price / LTM sales:
5.35x
EV / EBIT:
--
EV / Revenue:
5.20x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
1,890.92x
Price / Operating cash flow:
1,944.03x
Enterprise value / EBITDA:
1,087.51x
Gross Profit (TTM):
$498.8M
Return On Assets:
-12.07%
Net Income Margin (TTM):
-13.68%
Return On Equity:
-17.68%
Return On Invested Capital:
-17.68%
Operating Margin:
-4.34%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $358.9M | $469.3M | $574.5M | $126.4M | $153.4M | |
| Gross Profit | $319.3M | $414.1M | $498.8M | $111.9M | $133.5M | |
| Operating Income | -$20.5M | -$7.9M | -$42.4M | $4.8M | -$6.7M | |
| EBITDA | -$12.5M | $12M | -$34.9M | $7.8M | -$7.2M | |
| Diluted EPS | -$0.42 | -$0.06 | -$1.35 | $0.05 | -$0.31 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $199.5M | $228.2M | $410.6M | $469.1M | $263.4M | |
| Total Assets | $205.8M | $292.4M | $487.8M | $548.8M | $697.2M | |
| Current Liabilities | $14.3M | $29.5M | $42.3M | $66.1M | $148.8M | |
| Total Liabilities | $14.3M | $58.1M | $72.7M | $96.7M | $262.5M | |
| Total Equity | $191.5M | $234.4M | $415.1M | $452.1M | $434.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$10.2M | $34.9M | $14.2M | $15.9M | $2.7M | |
| Cash From Investing | -$164.6M | -$31.5M | -$60.6M | $11.8M | -$34.3M | |
| Cash From Financing | $178.2M | $1.9M | -$1.8M | $3.5M | $2.4M | |
| Free Cash Flow | -$21.1M | $29.4M | $1.6M | $14.3M | -$995K | |
NARI
Sector
Market Cap
$3.1B
$45.9M
Price % of 52-Week High
79.52%
46.95%
Dividend Yield
0%
0%
Shareholder Yield
-0.41%
-0.6%
1-Year Price Total Return
-19.5%
-32.15%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$54.37
200-day SMA
Buy
Level
$46.97
Bollinger Bands (100)
Buy
Level
43.03 - 52.17
Chaikin Money Flow
Sell
Level
-14.3M
20-day SMA
Sell
Level
$54.04
Relative Strength Index (RSI14)
Sell
Level
49.65
ADX Line
Sell
Level
28.27
Williams %R
Neutral
Level
-70.5336
50-day SMA
Buy
Level
$50.76
MACD (12, 26)
Buy
Level
0.96
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Sell
Level
-8.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (11.6852)
Buy
CA Score
(Annual)
Level (1.0383)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (8.0524)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system and others. Geographically, the company generates majority of its revenue from United States and rest from International markets.
Stock Forecast FAQ
In the current month, NARI has received 9 Buy ratings 5 Hold ratings, and 0 Sell ratings. The NARI average analyst price target in the past 3 months is $66.59.
-
Where Will Inari Medical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Inari Medical share price will rise to $66.59 per share over the next 12 months.
-
What Do Analysts Say About Inari Medical?
Analysts are divided on their view about Inari Medical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Inari Medical is a Sell and believe this share price will drop from its current level to $50.00.
-
What Is Inari Medical's Price Target?
The price target for Inari Medical over the next 1-year time period is forecast to be $66.59 according to 14 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is NARI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Inari Medical is a Buy. 9 of 14 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NARI?
You can purchase shares of Inari Medical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Inari Medical shares.
-
What Is The Inari Medical Share Price Today?
Inari Medical was last trading at $52.95 per share. This represents the most recent stock quote for Inari Medical. Yesterday, Inari Medical closed at $52.97 per share.
-
How To Buy Inari Medical Stock Online?
In order to purchase Inari Medical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Uber Stock a Buy on the Dip?
Shares of Uber Technologies (NYSE:UBER) have been fading fast in…
Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 28
Lemonade [LMND] is down 10.69% over the past day.
Sell
50
TSLL alert for Dec 28
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 9.92% over the past day.
Buy
63
SMLR alert for Dec 28
Semler Scientific [SMLR] is down 9.65% over the past day.
